Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial

Leiter L. A., Shestakova M. V., Satman I.

DIABETOLOGY & METABOLIC SYNDROME, cilt.10, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1186/s13098-018-0331-8
  • Dergi Adı: DIABETOLOGY & METABOLIC SYNDROME
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Type 2 diabetes, Gliclazide, Glycemic control, Tolerability, Real-world, CARDIOVASCULAR OUTCOMES, RAMADAN, HYPOGLYCEMIA, EMPAGLIFLOZIN, SULFONYLUREA, SAXAGLIPTIN, SITAGLIPTIN, MORTALITY
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the effectiveness of gliclazide modified release (MR) 60 mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment.